Pharmacological characterization of novel A3 adenosine receptor- selective antagonists

Neuropharmacology

Volumn 36, Issue 9, 1997, Pages 1157-1165

  Jacobson, Kenneth A ^a   Park, Kyung Sun ^a   Jiang, Ji Long ^a   Kim, Yong Chul ^a   Olah, Mark E ^b   Stiles, Gary L ^b   Ji, Xiao Duo ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Adenosine A3 receptor; Adenylate cyclase; Dihydropyridine; Flavonoid; Guanine nucleotides; Triazoloquinazoline; Tumor necrosis factor

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENYLATE CYCLASE; DIHYDROPYRIDINE DERIVATIVE; FLAVONOID; MRS 1067; MRS 1097; PHENYLISOPROPYLADENOSINE; TRIAZOLOQUINAZOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING COMPETITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; RECEPTOR BLOCKING;

EID: 0030694505     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00104-4     Document Type: Review

References (40)

1. 2+-ionophore-induced secretion in a rat mast-cell line. Journal of Pharmacological Experimental Therapy 276: 837-845.
2. Alunlakshana O. and Schild H. O. (1959) British Journal of Pharmacology and Chemotherapy 14: 48.
3. 3 receptors in mast-cells. Trends in Pharmacological Science 15: 13-14.
4. Buttini M., Appel K., Sauter A., Gebicke-Haerter P. J. and Boddeke H. W. (1996) Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience 71: 1-16.
5. 3 receptor agonists on mammalian astrocytes: protection at low concentrations and apoptosis at high concentrations. Drug Development Research 37: 77.
6. Daubener W., Remscheid C., Nockemann S., Pilz K., Seghrouchni S., Mackenzie C. and Hadding U. (1996) Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-gamma and tumor necrosis factor-alpha. European Journal of Immunology 26: 487-492.
7. 1 receptor mediated responses in rat hippocampus. Journal of Neuroscience 17: 607-614.
8. Haas R., Bartels H., Topley N., Hadam M., Kohler L., Goppelt-Strube M. and Resch K. (1989) TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens. European Journal of Cellular Biology 48: 282-293.
9. 3 adenosine receptors: design of selective ligands and therapeutic prospects. Drugs of the Future 20: 689-699.
10. 3 adenosine receptor antagonists. Drug Development Research 37: 131.
11. Ji X.-D., Melman N. and Jacobson K. A. (1996) Interactions of flavonoids and other phytochemicals with adenosine receptors. Journal of Medical Chemistry 39: 781-788.
12. 3 adenosine receptor antagonists. Journal of Medical Chemistry 39: 4667-4675.
13. 3 adenosine receptor antagonists. Journal of Medical Chemistry 40: 2596-2608.
14. Karton Y., Jiang J.-L., Ji X.-D., Melman N., Olah M. E., Stiles G. L. and Jacobson K. A. (1996) Synthesis and biological-activities of flavonoid derivatives as as adenosine receptor antagonists. Journal of Medical Chemistry 39: 2293-2301.
15. 3-adenosine receptors. Journal of Medical Chemistry 37: 3614-3621.
16. 3 receptor subtype. Journal of Medical Chemistry 39: 4142-4148.
17. 3 receptor agonists. Biochemistry and Biophysics Research Communication 219: 904-910.
18. 2+ and induces apoptosis. Drug Development Research 37: 182.
19. Kordek R., Nerurkar V. R., Liberski P. P., Isaacson S., Yanagihara R. and Gajdusek D. C. (1996) Heightened expression of tumor necrosis factor alpha, interleukin1 alpha, and glial fibrillary acidic protein in experimental Creutzfeldt-Jakob disease in mice. Proceedings of the National Academy of Science of the U.S.A. 93: 9754-9758.
20. 35S]-GTP-γ-S binding mediated by human muscarinic m1-m4 receptors: antagonist studies. British Journal of Pharmacology 109: 1220-1227.
21. 1 adenosine receptor with receptor/G protein complexes in rats-brain membranes. Molecular Pharmacology 49: 915-926.
22. 3 adenosine receptor. Molecular Pharmacology 45: 978-982.
23. Redford E. J., Hall S. M. and Smith K. J. (1995) Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 118: 869-878.
24. Rossi F. and Bianchini E. (1996) Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Biochemistry and Biophysics Research Communication 225: 474-478.
25. 3 adenosine receptors. Journal of Immunology 156: 3435-3442.
26. Salomon Y., Londos C. and Rodbell M. (1974) A highly sensitive adenylate cyclase assay. Analytical Biochemistry 58: 541-548.
27. 3 adenosine receptor. Proceedings of the National Academy of Science of the U.S.A. 90: 10365-10369.
28. 1-antagonists for treatment of cognitive deficits. Nucleosides and Nucleotides 10: 1067-1076.
29. Sheng W. S., Hu S., Lamkin A., Peterson P. K. and Chao C. C. (1996) Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/c mice. Clinical Immunology and Immunopathology 81: 161-167.
30. 2 antagonists. Journal of Medical Chemistry 35: 2342-2345.
31. 3 receptor agonist. Journal of Basic and Clinical Physiology and Pharmacology, in press.
32. Sun D., Hu X., Shah R., Zhang L. and Coleclough C. (1996) Production of tumor necrosis factor-alpha as a result of glia-T-cell interaction correlates with the pathogenic activity of myelin basic protein-reactive T cells in experimental autoimmune encephalomyelitis. Journal of Neuroscience Research 45: 400-409.
33. Tan S. V., Guiloff R. J., Henderson D. C., Gazzard B. G. and Miller R. (1996) AIDS-associated vacuolar myelopathy and tumor necrosis factor-α (TNFα). Journal of Neurological Science 138: 134-144.
34. 3 receptors. Journal of Medical Chemistry 39: 2980-2989.
35. 3 receptor stimulation and cerebral ischemia. European Journal of Pharmacology 263: 59-67.
36. 1 receptors and protection against NMDA-induced seizures. European Journal of Pharmacology 283: 185-192.
37. von Lubitz D. K. J. E., Lin R. -C., Paul I. A., Beenhakker M., Boyd M., Bischofberger N. and Jacobson K. A. 1996a Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. European Journal of Pharmacology 316: 171-179.
38. von Lubitz D. K. J. E., Lin R. C. S., Sei Y., Boyd M., Abbracchio M., Bischofberger N. and Jacobson K. A. 1996b Adenosine receptors and ischemic brain injury: a hope or a disaster? Drug Development Research 37: 140.
39. 3 antagonists Biochemistry and Biophysics Research Communication 232: 317-322.
40. 3 adenosine receptor. Proceedings of the National Academy of Science of the U.S.A. 89: 7432-7436.